ACE and chronic kidney disease: The Angiotensin-Converting Enzyme Inhibitors and Kidney Protection (AIPRI) trial compared ACEi and benazepril to a placebo in patients with mild to moderate CKD (mean GFR—37.1 mL/min/1.73 m2), mostly without diabetes, to assess its effect on CKD progression (doubling of serum creatinine or ESKD comprised the primary endpoint).